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Family health history is widely accepted as a critical com-ponent of patient care. It serves as one of the strongest 
predictors of disease risk, provides information about envi-
ronmental exposures, and has implications for the health of 
other family members. Many guidelines for screening and 
prevention—for instance, those of the American College of 
Cardiology for cardiovascular disease [1] and those of the 
American Gastroenterological Association for colon cancer 
[2]—strongly recommend (based on Level 1 evidence) that 
primary care providers collect family health history for dis-
ease risk stratification and risk management.
However, there are several barriers to gathering a family 
health history that is detailed enough to perform risk strati-
fication and to guide clinical care: lack of time, due to com-
peting clinical demands [3-7]; limitations in the patient’s 
knowledge of his or her family’s health history [8]; lack of 
reimbursement for the time spent collecting the history [9]; 
and lack of training in gathering family health history [3]. In 
addition, interpreting family health history information is 
difficult, particularly when this information is not available 
at the point of care, when it is not presented in a way that 
facilitates synthesis (eg, when it is scattered throughout 
the medical record and inconsistently formatted), or when 
it is not clearly actionable [9]. Unfortunately, adoption of 
electronic medical records (EMRs) has not improved fam-
ily health history collection rates, and EMRs do not address 
the barriers listed previously [10]. This finding is supported 
by a review conducted by our group (results of which are 
published in this issue on pages 279-286) [11] that com-
pares family health histories documented in paper charts 
(less than 4% of which were high-quality family health his-
tories) with those documented in EMRs at the same clinic 
(less than 1% of which were high-quality family health 
histories).
Despite the limitations of EMRs, advances in technol-
ogy are a key to overcoming many, if not all, of the barriers 
to family health history collection and use. For example, 
computer-based software programs that are referred to as 
“patient-facing” allow direct entry of family health history 
information by patients, which avoids the pressure to collect 
the data during the primary care appointment and permits 
patients adequate time to collect the necessary information 
from relatives. Such programs can also be linked to educa-
tion on how to collect family histories, and they use auto-
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mated algorithms to generate clinical decision support for 
analysis and interpretation of the history collected.
In 2004, the Genomedical Connection—a collabora-
tion on the part of Duke University, the University of North 
Carolina at Greensboro, and Cone Health System—obtained 
funding from the US Department of Defense to implement 
the genomic medicine model for primary care. The model 
is described in more detail elsewhere [12]. Briefly, it inter-
weaves education, family health history collection, and 
recommendations for family health history risk-based pre-
vention strategies within the clinical workflow of primary 
care practices. At the core of this model was the develop-
ment of a self-administered, patient-facing computerized 
program, called MeTree, which gathers family health history 
from patients and generates decision support for patients 
and providers. In this paper, we describe the conceptual 
foundation, development, and validation of MeTree and 
compare its features with those of existing decision support 
programs based on family health history.
Methods
Program design goals. When we began developing 
MeTree in 2004, our clinical experience with family health 
history collection, the published literature, and a review of 
existing programs led us to conclude that a family health 
history software program should have the following charac-
teristics, in order to be acceptable within clinical practice: 
It should improve clinical workflow by having patients enter 
their own family health history prior to an appointment with 
the provider; it should have point-of-care risk stratification; 
and it should facilitate uptake of risk-stratified preventive 
care recommendations that are clear, action-oriented, and 
evidence-based [13-15]. Therefore, we developed the follow-
ing design goals for MeTree: (1) to develop a family health 
history collection interface that is easy for patients to use 
and that facilitates the collection of all the necessary com-
ponents to perform risk stratification (ie, a full 3-generation 
pedigree with age of disease onset, current age or age at 
death, and cause of death for each relative); (2) to provide 
lay-level and technical decision support that is clinically 
actionable for providers and easy for patients and provid-
ers to understand; (3) to base decision support on guide-
lines that are widely accepted by primary care physicians; 
and (4) to capitalize on the patient-provider encounter to 
encourage discussions of preventive health and disease risk 
management.
MeTree description. MeTree, a stand-alone Web-based 
program, has 2 components: family health history collec-
tion and decision support. These 2 components were devel-
oped concurrently in order to maximize the effectiveness of 
each. For example, the Gail model [16, 17] was incorporated 
within the decision support component to identify women 
for whom breast cancer chemoprevention should be consid-
ered. Including this model and associated questions regard-
ing chemoprevention and its contraindications required the 
addition of questions that are not routinely collected by fam-
ily health history screening programs. 
Family health history collection and decision support 
were developed by a team of 4 genetic counselors (with 
expertise in adult, pediatric, and cancer genetics), 3 medi-
cal geneticists, a cardiologist, a health behaviorist, 2 medi-
cal oncologists, and 3 experts in information technology. 
An iterative Delphi-based approach [18], along with a con-
current literature review, was used to reach a consensus 
regarding which professional guidelines and expert opinions 
to base the algorithms on and which conditions to include. 
Given that MeTree is intended for use in primary care clini-
cal practices, preference was given to guidelines with which 
primary care physicians would be familiar (eg, those of the 
US Preventive Services Task Force and the American Cancer 
Society).
Family health history collection. The family health history 
collection component is the main patient interface. Patients 
use a Web-based survey that first establishes the family’s 
structure, with the names and ages (current age or age at 
death) for 4 generations of relatives, and then identifies 
which relatives have been affected by any of 48 potential 
conditions (See Table 1). These conditions were selected by 
compiling a list of important familial and hereditary condi-
tions and ranking them based on the strength of their famil-
ial risk and their importance to primary care providers. In 
order to maximize the effectiveness of the tool while mini-
mizing the burden of using it, only the top-ranked 48 condi-
tions were incorporated into MeTree.
To facilitate its ease of use, MeTree runs in full-screen 
mode, showing only questions and response fields, with-
out toolbars or menus that could clutter the window. All 
fields are touch-screen capable, and fonts and buttons are 
large and easy to read. Survey questions are written at an 
8th-grade reading level when possible. Use of branching 
questionnaire logic allows MeTree to skip irrelevant survey 
question screens, which minimizes the time patients need 
to complete the survey. Family health histories can also be 
updated and the algorithms rerun as needed. 
Of note, a second MeTree interface was developed in 
2012, employing a graphical user interface and tablet tech-
nology. Rather than relying on radio buttons and text-based 
input of family structure and health history, the new inter-
face uses graphics, drag-and-drop technology for adding 
relatives, and drop-down lists that expand and minimize 
as desired to facilitate quick selection of health history by 
relative. Zooming, panning, and swiping facilitate rapid data 
entry.
Decision support. MeTree provides decision support for 
diseases that have a strong impact on population health, 
either because they are highly prevalent or because they 
have high morbidity and/or mortality (high clinical valid-
ity). The program also provides established risk-stratified 
screening and preventive care strategies that are known to 
have high clinical utility. Using these criteria, 5 pilot diseases 
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(breast cancer, ovarian cancer, colon cancer, thrombosis, 
and risk for a hereditary cancer syndrome) were chosen to 
demonstrate MeTree’s effectiveness and acceptability. The 
decision support process risk-stratifies patients into one of 
several risk levels according to their family health history, 
and it then links the risk level to an action-oriented risk-
management recommendation.
To foster discussion about risk, risk management, and 
disease prevention, decision support and structured family 
health history documents are given to patients (pedigree 
and patient report) and providers (pedigree, family health 
history in a tabular format, and provider report) prior to 
the scheduled appointment time. These documents are 
designed to be simple to read, with straightforward mes-
sages that are specific to the intended recipient. The patient 
report (Figure 1), written at an 8th-grade reading level, sum-
marizes key points that patients might want to discuss with 
the provider regarding their family health history–based risk 
for the pilot diseases. The provider report (Figure 2) begins 
with an evidence-based action plan driven by the patient’s 
estimated disease risk; this action plan is followed by a more 
detailed description of the criteria triggering each recom-
mendation, along with relevant references. The increasing 
level of detail available in the provider report allows for just-
in-time education determined by provider interest, curiosity, 
or need.
Decision support risk categories and their associated 
action-oriented risk-management strategies for thrombosis 
are as follows (in order of decreasing risk): genetic testing 
for inherited thrombophilia, with referral to genetic counsel-
ing; referral to genetic counseling alone; or no recommended 
intervention. Categorization for thrombosis is based on 
guidelines of the American College of Chest Physicians [20].
Decision support risk categories and their associated 
action-oriented risk-management strategies for breast can-
cer, ovarian cancer, colorectal cancer, and hereditary cancer 
syndrome are as follows (in order of decreasing risk): refer-
ral to genetic counseling, increased personal and familial 
risk managed by provider, and routine population-based 
screening. An algorithm evolved in which patients who met 
the criteria for genetic counseling referral were identified 
first, and then the patients at familial or population risk were 
identified. Women without a personal history of breast or 
ovarian cancer are selected for genetic counseling referral if 
they meet US Preventive Services Task Force guidelines [21]. 
However, these guidelines do not apply to men or to women 
who already have breast or ovarian cancer, so expert opinion 
[22] and the published guidelines of the National Society of 
Genetic Counselors [23] are used to select patients from 
these 2 groups who should be referred to a genetic coun-
selor due to elevated risk of hereditary breast and ovarian 
cancer syndrome. Patients who meet the Amsterdam II 
diagnostic criteria for hereditary nonpolyposis colorectal 
cancer [24] or criteria established based on expert opinion 
[22] are selected for referral to discuss hereditary colorectal 
cancer risk.
table 1.
Health Conditions Included in MeTree
Cancers Other conditions Hereditary cancer syndromes
Brain cancer Alzheimer disease/dementia Hereditary breast and ovarian cancer (BRCA1/BRCA2 genes)
Breast cancer Anemia Hereditary nonpolyposis colon cancer (MLH1/MSH2/MSH6 genes)
Cervical cancer Asthma Familial adenomatous polyposis (APC gene)
Colon cancer Blood clots in veins Li Fraumeni syndrome (TP53 gene)
Kidney cancer Colon polyps Cowden syndrome (PTEN gene)
Leukemia Diabetes Other cancer syndromes
Liver cancer Glaucoma 
Lung cancer Heart attack 
Lymphoma High blood pressure 
Melanoma High cholesterol levels 
Ovarian cancer Inflammatory bowel disease 
Pancreatic cancer Lupus 
Prostate cancer Macular degeneration 
Skin cancer (not  
 melanoma) Multiple miscarriages 
Small bowel cancer Multiple sclerosis 
Stomach cancer Osteoporosis 
Testicular cancer Parkinson disease 
Thyroid cancer Rheumatoid arthritis 
Uterine cancer Seizures 
Unknown cancer Stroke 
Other cancer, specify Thyroid disease 
Note. Modified from Orlando et al. [19]
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The category “personal and familial risk management” 
includes patients whose risk for the 3 types of cancer does 
not warrant genetic counseling referral but is sufficient to 
merit consideration of surveillance or chemoprevention. 
Breast magnetic resonance imaging as an adjunct to mam-
mography is recommended for those who meet American 
Cancer Society guidelines for breast cancer risk (eg, those 
with a lifetime risk greater than 20%) [25]. Lifetime risk is 
calculated using BRCAPRO, a statistical model and software 
program using Mendelian genetics and Bayesian updat-
ing. BRCAPRO incorporates the following information for 
patients and their first-degree and second-degree relatives 
(including those without cancer): sex; current age or age at 
death; diagnosis of breast cancer, second primary breast can-
cer, or ovarian cancer; age at cancer diagnosis; and presence 
or absence of Ashkenazi Jewish ancestry [26]. Breast can-
cer chemoprevention with tamoxifen or raloxifene is recom-
mended for women aged 35–60 years whose 5-year breast 
cancer risk exceeds 1.65% [27, 28]. Five-year risk is calcu-
lated using the Gail model [16]. BRCAPRO and Gail model 
risk scores are included in the provider’s report. Colorectal 
cancer surveillance is recommended for those who meet 
the joint guidelines of the American Cancer Society, the 
US Multi-Society Task Force on Colorectal Cancer, and the 
American College of Radiology [29]; such surveillance often 
involves scheduling the first colonoscopy at an earlier age 
and performing follow-up colonoscopies more frequently.
“Average risk” patients who do not meet criteria for 
genetic counseling referral or familial or personal risk man-
agement are managed according to the American Cancer 
Society recommendations for individuals at population risk 
for cancer [30].
Genetic counselors on the team are using their clinical 
expertise and regular literature reviews to ensure that the 
clinical algorithms and decision support recommendations 
remain current. One of the genetic counselors reviews a 
random sample of pedigrees, patient reports, and provider 
reports on a monthly basis to identify inaccuracies and 
misclassifications. These are reported to a working group 
of content and information technology experts, who review 
and correct the algorithm code and make content changes 
as necessary.
Coding. Several open-source computer software appli-
cations are incorporated into MeTree. These include PHP 
(version 5.4.9), a widely used general-purpose scripting 
language that is especially suited for Web development; 
Apache HTTP Server, a popular Web server; and Linux, a free 
UNIX-type operating system. Other programming resources 
include C++, which is used to calculate the Gail Score for 
5-year breast cancer risk; R, an open-source statistical pack-
age used to calculate lifetime breast cancer risk using the 
BRCAPRO model with the BayesMendel R library; VBScript 
(Visual Basic Scripting Edition), a scripting tool provided 
with the Microsoft Windows operating system that is used 
figure 1.
Example of Decision Support: Patient Report
Note. Reprinted from Orlando et al [19]. 
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to load provider and patient visit data; and Microsoft SQL 
Server, a relational database management system used to 
model decision support algorithms.
The MeTree Admin utility is a Web-based application writ-
ten in PHP that provides administrators and clinical coordi-
nators secure access to patient data and questionnaire data. 
It permits updating of patient contacts (letters, phone con-
versations, etc), mail merging of data sources for printing 
introduction letters for prospective participants, printing of 
postquestionnaire pedigree and summary reports, and display 
of important data elements for patient tracking and ongoing 
quality evaluation. For example, it can display demograph-
ics, patients by date of visit, questionnaires completed, and 
patients who were no-shows or who declined participation.
Validation
To optimize the collection of family health history and the 
development of decision support algorithms and reports, 
pilot testing was carried out in several phases prior to imple-
mentation of MeTree in primary care practices. The first 
phase involved testing with community volunteers, and 
the second phase involved testing with genetic counselors. 
Finally, the third phase was a 3-year pilot test within 2 differ-
ent primary care practices, during which feedback from pro-
viders and patients was used to optimize clinical workflow 
and report content [31].
figure 2.
Example of Decision Support: Provider Report
Note. Reprinted from Orlando et al [19]. 
292 NCMJ vol. 74, no. 4
ncmedicaljournal.com
Community pilot program. The phrasing and clarity of 
the questions used to collect family health history were 
assessed via cognitive interviews with community volun-
teers, a technique that has been successfully used across 
diverse populations to ensure that health materials are 
understood as researchers intend [32-34]. Volunteers 
were acquired through convenience sampling: They were 
recruited from the pool of visitors and staff members enter-
ing Moses Cone Hospital and were offered a $20 gift card 
for participating. The volunteers were each asked to read 
the family health history collection questions one at a time 
and then tell the interviewer, a team member trained in 
cognitive interviewing, what the question meant to them 
and whether the question was clear. Usability of the family 
health history collection interface was evaluated by asking 
volunteers to complete the family health history collection 
and then to comment on screen layout, skip patterns, fonts, 
button size, and other formatting features. The amount of 
time required to complete the collection of family health his-
tory was tracked for each volunteer. Based on these results, 
the development team revised the content and presentation 
of the questions and then repeated the item phrasing and 
usability testing until saturation was reached—that is, until 
no new comments were given.
Genetic counselor pilot program. Ten cancer counselors 
and 3 thrombophilia genetic counselors, all of whom had had 
no prior interaction with MeTree, were recruited through 
local professional networks to assess the usability, quality, 
and thoroughness of the decision support content and the 
accuracy and clarity of the risk algorithms and recommen-
dations. Each counselor entered at least 5 sample cases 
into MeTree, reviewed the decision support output, and 
completed an online survey developed by the study team. 
The following are examples of questions used to assess 
usability: “What problems do you foresee patients having 
with MeTree?”; “On a scale of 1 (not easy at all) to 5 (very 
easy), how easy will it be for your patients to understand the 
questions?”; and “What technical problems, if any, did you 
encounter?” Additional questions were used to assess con-
tent, such as: “What questions, if any, did you expect to see 
that pertain to cancer risk, but didn’t?”; “Is the pedigree and 
risk report generated by MeTree more helpful than the typi-
cal referral information you receive (Y/N)?”; and “In your 
professional opinion, are the recommendations on the pro-
vider report consistent with the sample patient’s level of risk 
for colon cancer?” The algorithms and reports were revised 
to address areas of deficiency or inaccuracy.
Clinical practice pilot program. MeTree was integrated into 
2 community-based primary care clinical practices in the 
Cone Health system in Greensboro, North Carolina, as part 
of a hybrid type II implementation-effectiveness trial. (More 
information about how such trials are designed can be found 
in a 2012 article by Curran and colleagues [35].) Details 
of our study design can be found in the published protocol 
table 2.
Features of Electronic Primary Care Decision Support Programs
      Availability Public 
   Who enters Who receives of output at availability 
Program Diseases covered the information? the output? point of care? of program
MeTree colon cancer, breast cancer,  Patient (online Patient and Yes In future 
  ovarian cancer, and hereditary  or in the physician 
  cancer syndrome risk physician’s office) 
Program described by  colon cancer Physician Physician Yes Unknown 
 Schroy et al. [36]   
Genetic Risk Assessment  breast cancera Patient (in the Patient, clinical Yes Unknown 
 in the Clinical   physician’s office) nurse specialist,   
 Environment    or physician 
 (GRACE) [37]    
Family Healthware [38] coronary heart disease,  Patient (online) Patient or Unknown No 
  diabetes, stroke, colon   physician 
  cancer, breast cancer, and  
  ovarian cancer    
Family HealthLink [39]  coronary heart disease,  Patient (online) Patient No Yes 
  cancer 
Cancer Risk Intake colon cancer Patient (in the  Patient and Yes No 
 System  physician’s office) physician
MyGenerations [40] cancer Patient (online) Patient No Yes
HughesRiskApps [41] breast and ovarian cancer Patient or clinician Patient and Yes Yes 
   (can be revised  physician 
   online or in the  
   physician’s office)
Health Heritage [13] 87 diseases: including  Patient (online) Patient No No 
  multiple cancers, diabetes,  
  neuromuscular diseases, and  
  cardiovascular diseases
aGRACE is designed for use only with women who have a family history of breast cancer.
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paper [19]. The 2 practices, which have served the commu-
nity for almost 20 years, care for more than 21,000 unique 
patients annually and are staffed by 13 primary care provid-
ers (12 internal medicine or family medicine physicians and 
1 nurse practitioner). Both practices used paper charts at the 
time of implementation, but each converted to an EMR sys-
tem (although to 2 different systems) during the 3-year pilot 
program. During the first 6 months of the trial, implementa-
tion research methodology was used to assess and adapt 
the implementation effort, and a clinical expert assessed the 
accuracy of the risk algorithms and recommendations.
To address the quality and impact of integration into clin-
ical workflow, a study coordinator was embedded into each 
clinical practice. The study coordinators verbally conducted 
daily cycles of feedback from stakeholders (patients, clinic 
staff, and providers), and the lead investigator, an internist 
with training in health services research, conducted monthly 
cycles of verbal stakeholder feedback. The study coordi-
nator recorded all questions asked by patients during the 
visit as well as any unprompted questions asked by clinic 
staff members and providers; the study coordinator also 
asked staff members and providers specific questions. All 
stakeholders were encouraged to provide open and hon-
est responses to open-ended questions such as: “What has 
your experience been so far?”; “What could we improve?”; 
What barriers are you encountering?”; “Do you have any 
concerns?”; “Is the report content and format clear and 
helpful?”; and “How and when are you receiving reports?” 
Responses were clarified using funneling questions to elicit 
greater detail regarding who, what, why, how, and when; the 
clarified responses were then used to adapt components 
of the program (including usability, decision support docu-
ments, and workflow integration) that did not meet stake-
holder needs. Clinic staff members (nurses and clerks) were 
asked the same questions as providers, but data for the 
2 groups were analyzed separately.
To assess the accuracy of the programming, coding, algo-
rithms, and report output, a genetic counselor reviewed 
every pedigree and its associated recommendation reports 
for patients enrolled during the first 6 months of the pilot 
program. Mismatches between pedigree input and algo-
rithm or report output were identified and referred to a 
second genetic counselor for review. When both genetic 
counselors agreed that a mismatch was present, coding 
errors were identified and corrected.
Results
Community pilot program. A total of 19 individuals com-
pleted cognitive interviews during 3 iterative cycles of data 
collection and MeTree revision, after which saturation was 
reached. Among the 19 cognitive interviewees, 11 were 
female and 8 were male; 7 were African American and 11 
were white; and 14 of the interviewees had some college or 
less education. Age was recorded in 5-year increments, and 
interviewees included at least 1 person in each age bracket 
from 18 to 70+ years. Interviewees suggested ways of sim-
plifying and organizing MeTree’s questions and proposed 
that disease definitions be added. As a result of these sug-
gestions, longer questions were broken into multiple shorter 
questions, questions about maternal and paternal relatives 
were organized more intuitively, and pop-up boxes were 
added that defined diseases in lay terminology.
During 3 iterative cycles of usability testing, 22 individu-
als (16 females and 6 males; 7 African Americans and 15 
whites) completed MeTree’s family health history collec-
tion. These individuals were diverse in education (8 had less 
than a bachelor’s degree) and age (the only age bracket that 
was not represented was 65–69 years). The average time 
to complete MeTree was 20 minutes. Comments from vol-
unteers included recommendations to increase the size of 
the font and buttons, to provide clearer error messages, to 
employ fewer drop-down lists, to give users the option of 
using either a mouse or a touch screen, to add “don’t know” 
as a response option, to emphasize important instructional 
words, and to make the status bar more prominent. The 
programming was also revised to allow users to more easily 
remove relatives who had been entered by mistake and to 
automatically save information as it is entered, thus allowing 
users to jump between screens.
Genetic counselor pilot program. Feedback from the can-
cer genetic counselors regarding MeTree’s usability, ques-
tion content, printed reports, and algorithms included the 
following recommendations: to facilitate navigation by 
employing skip patterns (eg, avoiding cancer-specific ques-
tions in unaffected relatives); to allow users to quickly and 
easily move back and forth between questions; and to ask 
about cancer genetic testing in the patient and his or her 
relatives. To address these suggestions, program develop-
ers added skip patterns throughout the program, “bread 
crumbs” to allow users to find earlier pages more easily, and 
a series of questions about specific tests for hereditary can-
cer syndromes. 
Suggestions regarding report content and clarity, which 
made up the bulk of the feedback, included proposals that 
the following information be added: colon cancer recom-
mendations based on polyp histology (adenomatous versus 
nonadenomatous); recently published guidelines on breast 
magnetic resonance imaging screening [25] and colorectal 
cancer surveillance [29]; and screening and surveillance 
recommendations for patients who are referred for genetic 
counseling, in case they decline counseling. Reports were 
revised accordingly. 
Suggestions regarding algorithms included a recom-
mendation that patients meeting Amsterdam II criteria be 
referred to genetic counseling for Lynch syndrome screen-
ing [24], and a recommendation that maternal and paternal 
relatives be coded separately to restrict the counting of rela-
tives to one side of the family. This last suggestion was due 
to concern regarding over-referral to counseling, because 
some of MeTree’s recommendations are based on the num-
294 NCMJ vol. 74, no. 4
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ber of affected relatives (eg, having 3 relatives with the same 
cancer merits referral to genetic counseling).
Clinical practice pilot. The implementation of feedback 
from clinical staff was uniformly positive, and no changes 
were recommended. Among the 192 patients (mean age, 
58 years; 58% female; 75% white) who were enrolled in the 
study during the first 6 months, feedback was also uniformly 
positive, except from some individuals older than 60 years 
who were uncomfortable using a computer. In those cases, 
no actionable feedback was provided. Providers indicated 
that patient flow was unaffected by integration of MeTree 
and that patient discussions and the clinical encounter were 
improved by the presence of the reports. 
However, providers did make several recommendations 
regarding report content and organization. Initially, the 
beginning of the reports contained a risk management rec-
ommendation along with a significant amount of detail sup-
porting the recommendation. In addition, to avoid offending 
providers, most recommendations were passively worded 
using terms such as “consider a discussion about . . .” All 
providers agreed that reorganizing the reports to highlight 
simple, clear, action-oriented plans was crucial to usability 
during normal clinic workflow. The additional details sup-
porting the recommendations, such as the personal history 
or family health history triggers that elicited the recom-
mendation; “special cases,” such as when not to follow the 
recommendation; and a link to the guideline itself were all 
strongly endorsed as useful just-in-time education that the 
providers wanted to continue to see, but in a separate sec-
tion. They also requested the addition of clinical data sup-
porting the recommendation (including trial data, such as 
clinical validity and utility) and potential harms and benefits 
of the recommendation. Therefore, the report was modi-
fied to present a bulleted list of action items in a prominent 
section at the beginning of the report, followed by several 
sublevels of just-in-time education, each with an increasing 
level of detail to give providers the depth of knowledge they 
desired without negatively impacting their patient workflow.
Programming validation. During the genetic counselor 
review of pedigrees and reports for the 192 patients enrolled 
during the first 6 months of the clinical practice pilot, 
52 participants (27%) were identified as having 73 poten-
tial mismatches between the pedigree and the provider 
or patient report. After review by a second genetic coun-
selor, no error was found in 22 (30%) of the 73 potential 
mismatches, but the remaining 51 mismatches (70%) had 
errors that required programming revisions. Errors and solu-
tions within this group were as follows: With regard to for-
matting, 13 (25%) mismatches involved pedigree spacing 
that was off and needed to be revised. With regard to clar-
ity of the report’s contents, 2 (4%) mismatches occurred 
because a MeTree question was not clear, and those ques-
tions were revised for clarity; 10 (20%) of the mismatches 
occurred because the text of the provider reports and the 
patient reports was unclear, so that text was revised for clar-
ity; and 15 (29%) of the mismatches involved the pedigree 
being inconsistent with the reports to the provider and the 
patient, so relevant details were added to the pedigree, and 
a separate data report was generated. With regard to cod-
ing errors, 11 (22%) mismatches involved algorithm coding 
problems, so the coding was revised. Examples of coding 
corrections include adding an upper age limit to chemopre-
vention recommendations and adding affected maternal and 
paternal relatives separately. To maintain confidence in the 
accuracy of the coding, pedigrees were randomly reviewed 
for 1 year following the 6-month pilot phase, and no new 
errors were found.
Discussion
Primary care providers are expected to systematically 
collect family health history and to manage their patients’ 
disease risks accordingly, yet many provider-level, patient-
level, and system-level barriers in primary care impede the 
uptake of this deceptively complex activity [9]. This paper 
outlines the foundational goals, development, and stepwise 
validation of MeTree, a computerized, patient-entered fam-
ily health history collection and decision support program 
that addresses many of the barriers to the collection of 
high-quality family health histories and use of this informa-
tion for risk assessment. MeTree was adapted during each 
step of validation: testing with community volunteers for 
usability and understanding; testing with genetic counselors 
for usability, content, and accuracy; and testing in clinical 
practice for feasibility, uptake, and accuracy. The end result 
of this process is a valid tool optimized to promote uptake 
of family health history collection and implementation of 
guidelines for risk-stratified evidence-based prevention and 
screening in busy primary care practices.
A structured family health history is crucial to appropri-
ate risk assessment in asymptomatic or presymptomatic 
individuals. Compared with other markers of disease risk 
in this group (ie, clinical variables), family health histories 
are more readily available and have higher odds ratios for 
predicting disease, and the collection of a family health his-
tory is frequently the first (and sometimes only) step in risk 
stratification. In addition, a growing number of guidelines 
rely on risk stratification to guide the prevention and screen-
ing strategy. Examples of conditions for which guidelines 
rely on risk stratification include the conditions for which 
MeTree provides clinical decision support (breast and ovar-
ian cancer, colon cancer, hereditary cancer syndromes, and 
thrombosis) along with cardiovascular disease, cerebrovas-
cular disease, inherited cardiomyopathies and arrhythmias, 
and inherited neurologic conditions. Given that primary care 
practices are medical homes for all patients regardless of 
their health status, these practices are the ideal place to 
carry out risk assessment and risk-guided prevention strate-
gies, which places much of the emphasis (and the burden) 
on the primary care provider.
Our goal in developing MeTree was to relieve some of this 
295NCMJ vol. 74, no. 4
ncmedicaljournal.com
burden. MeTree has 5 of the 7 characteristics of the “ideal 
family history tool” described by Rich and colleagues [9]. 
MeTree is “patient-completed” and “adapted to patient age, 
gender, ethnicity, and common conditions” [9]. Our exten-
sive pilot testing via cognitive interviewing, usability testing, 
genetic counselor review, and provider review showed it to be 
“brief, understandable and easy to use” [9]. Finally, MeTree 
“contains clinical decision support” at the point of care and 
“branches and prioritizes based on clinical significance” [9]. 
This combination of attributes, MeTree’s focus on seamless 
integration within primary clinical practice workflow, and its 
emphasis on both the patient and the provider as recipients 
of different types of tailored information were unique at the 
time MeTree was developed. Table 2 shows a comparison 
of MeTree’s characteristics with those of currently available 
electronic tools for family health history collection and deci-
sion support.
One limitation of MeTree is the lack of integration with 
a medical record (the most common request from provid-
ers). To our knowledge, none of the existing family health 
history tools directly integrate into EMR systems, although 
there may be institutions where local adaptions have over-
come this barrier; these would be unique to the setting and 
permit only local integration. The reason for this lack of inte-
gration is simple, although not intuitive: Integration of a fam-
ily health history collection tool into an EMR system comes 
with considerable limitations and complexities. Each EMR 
system structures family health history differently, requests 
different types of information (often not based on the 
need for risk assessment), and uses nonstandard formats 
(despite the push for compatibility with Health Level Seven 
[HL7] standards of health care informatics interoperability). 
In addition, compatibility with one EMR system frequently 
does not permit compatibility with another EMR system, or 
even with the same EMR system implemented in a differ-
ent setting. With the current state of EMRs, the only way 
to directly integrate with EMRs would be to rebuild MeTree 
within each individual EMR system, restructuring their EMR 
data format in the process. The end result would be 100 dif-
ferent instances on 100 different systems, all of which would 
need algorithm maintenance and system support—an over-
whelming task for an academic group with limited time and 
resources. Before integration can feasibly proceed, EMR 
systems need to adopt standards for data structure, storage, 
and transmission across systems.
Another limitation is that, despite extensive piloting 
among stakeholder groups, implementation of MeTree has 
been studied in only 2 clinics within a single community set-
ting. Optimal performance in those clinics does not predict 
optimal performance in other settings. To promote broader 
uptake across a variety of settings, MeTree will need to be 
evaluated for uptake, fidelity, and performance in other 
types of settings.
The above limitations refer to the specific case of devel-
oping and validating MeTree; however, as a tool for clinical 
practice, its impact needs to be evaluated in the clinical envi-
ronment, which we are doing as part of the hybrid type II 
implementation-effectiveness study that recently concluded 
at the pilot clinics. In order to continue to serve our goals of 
improving patient care and offloading provider work, we also 
intend to continue to do the following things: (1) optimize 
workflow integration by promoting family health history 
data standards and develop a demonstration of EMR inte-
gration; (2) add decision support for other conditions with 
risk-stratified evidence-based primary prevention guide-
lines; (3) enhance patient reporting by taking advantage of 
apps, online tools, and other tools to facilitate understand-
ing and uptake of recommendations; and (4) incorporate 
patient behaviors, values, and preferences in the report’s 
output to further personalize recommendations and adapt 
them to each patient’s unique situation.  
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